FDA accepts application for new OA drug

(TradingMarkets.com) UPDATED 2009-11-19

The U.S. Food and Drug Administration (FDA) has accepted a French drugmaker's new drug application for its experimental osteoarthritis drug naproxcinod. The FDA will complete its review 10 months after submission, and it has set a date for a decision on the medication for July 24, 2010. Read full story >

See all Rheumatoid Arthritis News

Font size
- A
- A
- A
Email This
Bookmark

Was this helpful? Yes
Save

Note: All clinical content on this site is physician-reviewed, except material generated by our community members.

Featuring Content From:

We comply with the HONcode standard for
trustworthy health information: verify here.

By using this service, you accept our Terms of Use. Please read them. The consumer health information on is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2005-2010. The HealthCentral Network, Inc. All rights reserved.

FDA accepts application for new OA drug

People who read this also read...

What the community is saying...

The Love that Gets Us Through

Lene Andersen